Mogrify wins Life Science Innovation Award and Prof. Julian Gough named Academic Entrepreneur of the Year at Business Weekly Awards 2020
Mogrify recognized for furthering life science discovery for the benefit of human healthcare through direct cellular conversion technology
Co-founder and CSO receives award celebrating his achievements in establishing Mogrify
Cambridge, UK, 18 September 2020: Mogrify Limited (Mogrify®), a UK company aiming to transform the development of ex vivo cell therapies and pioneer the field of in vivo reprogramming therapies, today announced it had won the AstraZeneca Life Science Innovation category of the Business Weekly Awards. The award commends Mogrify in applying its proprietary direct cellular conversion technology to further the cause of life science discovery for the benefit of human healthcare. Prof. Julian Gough, Co-founder and CSO of Mogrify, received the Cambridge Enterprise Academic Entrepreneur of the Year award in recognition of his work as a life science innovator and founder of Mogrify.
Mogrify’s proprietary direct cellular conversion technology determines the conversion factors required to convert (ex vivo or in vivo) any target cell type from any source cell type. The Company is deploying this platform to engineer an evergreen and scalable source of cell types that exhibit efficacy and safety profiles necessary to address diseases with a high unmet clinical need, such as in ophthalmological, immunological, hematological, and other disease areas.
Prof. Gough is a leading bioinformatician and biotech entrepreneur who led the development and application of the Mogrify platform, which utilizes a systematic big-data approach (Rackham et al., Nature Genetics, 2016) developed over a 10-year period via a multi-national research collaboration. Graduating with a PhD in molecular biology from the University of Cambridge, Julian became Professor of Bioinformatics at the University of Bristol and is now Programme Leader at the MRC Laboratory of Molecular Biology in Cambridge. He has also successfully started a number of biotech companies.
Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: “Our team are committed to transforming healthcare for indications of high unmet clinical need. The award for Life Science Innovation attests to the potential of Mogrify’s platform and pioneering team to overcome safety, efficacy and scalability challenges for cell therapies and we are honored to have this recognized by the judges at this year’s esteemed business awards.
Julian is an outstanding scientist and entrepreneur who has worked tirelessly to advance Mogrify technology and drive its therapeutic application forward, paving the way for future treatments and inspiring those who work alongside him.”
Professor Julian Gough, Co-founder and CSO, Mogrify, said: “Following on from our previous success in the ‘Disruptive Technology’ category at last year’s Business Weekly Awards, I am delighted to see Mogrify go from strength to strength and achieve success again in 2020.
I am immensely proud to have been named ‘Academic Entrepreneur of the Year’ and would like to thank my peers who have supported me throughout my career and Mogrify’s talented team for their dedication and hard work in pioneering novel cell therapies.”
Since February 2019, Mogrify has raised over $20 million USD in seed and series A rounds and $2.5 million USD in grant funding, and has grown to a headcount over 60 of scientific, operational, and commercial staff.
For further information on Mogrify’s technology and leadership team, please visit:
Notes to Editors
Prof. Julian Gough
Co-founder and CSO, Mogrify
Dr. Darrin M. Disley, OBE
For high-resolution and alternate images please contact Zyme Communications.
For further information please contact:
Darrin M Disley, PhD, OBE
Tel: +44 (0)7811 996 942
Westwicke, an ICR Company (investor inquiries)
Tel: +1 (646) 277-1282
About Mogrify www.mogrify.co.uk
Mogrify has developed a proprietary direct cellular conversion technology, which makes it possible to transform (transmogrify) any mature human cell type into any other without going through a pluripotent stem cell- or progenitor cell-state.
The platform takes a systematic big-data approach to identify, from next-generation sequencing and gene-regulatory networks, the transcription factors (in vitro) or small molecules (in vivo), needed to convert a cell. By bypassing the stem cell-stage of cell transformation, Mogrify simultaneously addresses challenges associated with efficacy, safety and scalability.
Mogrify is deploying this platform to develop novel cell therapies addressing musculoskeletal, auto-immune, cancer immunotherapy, ocular and respiratory diseases as well as generating a broad IP position relating to cell conversions that exhibit safety, efficacy and scalable manufacturing profiles suitable for development as cell therapies.
Uniquely positioned to address a cell therapy market estimated to be $35 billion USD by 2023, Mogrify is commercializing its technology via IP licensing, product development, and drug development. Based in Cambridge, UK, the Company has raised over $20 million USD funding from Ahren Innovation Capital, Parkwalk, 24Haymarket, Dr. Darrin M. Disley, OBE and the University of Bristol Enterprise Fund III.